Literature DB >> 14980529

Molecular medicine for the brain: silencing of disease genes with RNA interference.

Beverly L Davidson1, Henry L Paulson.   

Abstract

The recent discovery of RNA interference (RNAi) has revolutionised biological research and now holds promise as a potential therapy for human diseases. Currently untreatable neurological diseases are especially attractive targets. Scientists have already succeeded in using RNAi to suppress dominant disease genes in vitro; in some cases, this suppression has been allele-specific, silencing the disease-causing allele while maintaining expression of the normal allele. The challenge now is to bring this powerful technology in vivo to animal models to suppress disease genes and correct disease phenotypes. In the confrontation of this challenge, research should benefit from recent advances in viral and non-viral delivery of therapy to the brain.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14980529     DOI: 10.1016/S1474-4422(04)00678-7

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  30 in total

Review 1.  RNA interference in neuroscience: progress and challenges.

Authors:  Victor M Miller; Henry L Paulson; Pedro Gonzalez-Alegre
Journal:  Cell Mol Neurobiol       Date:  2005-12       Impact factor: 5.046

Review 2.  Human gene therapy and imaging in neurological diseases.

Authors:  Andreas H Jacobs; Alexandra Winkler; Maria G Castro; Pedro Lowenstein
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

3.  Tailor-made RNAi knockdown against triplet repeat disease-causing alleles.

Authors:  Masaki Takahashi; Shoko Watanabe; Miho Murata; Hirokazu Furuya; Ichiro Kanazawa; Keiji Wada; Hirohiko Hohjoh
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-22       Impact factor: 11.205

Review 4.  RNAi therapeutics: principles, prospects and challenges.

Authors:  Lars Aagaard; John J Rossi
Journal:  Adv Drug Deliv Rev       Date:  2007-03-16       Impact factor: 15.470

5.  Efficient down-regulation of glia maturation factor expression in mouse brain and spinal cord.

Authors:  Smita Zaheer; Yanghong Wu; Xi Yang; Ramasamy Thangavel; Shailendra K Sahu; Asgar Zaheer
Journal:  Neurochem Res       Date:  2012-03-25       Impact factor: 3.996

6.  Drug delivery systems: Advanced technologies potentially applicable in personalized treatments.

Authors:  Jorge F Coelho; Paula C Ferreira; Patricia Alves; Rosemeyre Cordeiro; Ana C Fonseca; Joana R Góis; Maria H Gil
Journal:  EPMA J       Date:  2010-04-10       Impact factor: 6.543

Review 7.  Self-assembled lipid nanomedicines for siRNA tumor targeting.

Authors:  Yu-Cheng Tseng; Leaf Huang
Journal:  J Biomed Nanotechnol       Date:  2009-08       Impact factor: 4.099

Review 8.  Lipid-based nanotherapeutics for siRNA delivery.

Authors:  A Schroeder; C G Levins; C Cortez; R Langer; D G Anderson
Journal:  J Intern Med       Date:  2010-01       Impact factor: 8.989

9.  Selective cleavage of AChR cRNAs harbouring mutations underlying the slow channel myasthenic syndrome by hammerhead ribozymes.

Authors:  Amr Abdelgany; John Ealing; Matthew Wood; David Beeson
Journal:  J RNAi Gene Silencing       Date:  2005-07-28

10.  The role of integrins in cancer and the development of anti-integrin therapeutic agents for cancer therapy.

Authors:  Xinjie Lu; Dong Lu; Mike Scully; Vijay Kakkar
Journal:  Perspect Medicin Chem       Date:  2008-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.